RB1CC1 and p62/SQSTM1 abnormalities in human carcinogenesis, and their utilities on clinical application

采用肺癌组织芯片对p62/SQSTM1和RB1CC1的染色进行评分。RB1CC1仅在肺癌的胞浆中表达，提示肺癌预后不良。P62/SQSTM1积聚与患者的生存状况有关，尤其是同时表达p62/SQSTM1和RB1CC1的患者预后最差。P62/SQSTM1可能成为肺癌患者预后较差的生物标志物，在口腔鳞癌中，p62/SQSTM1可诱导口腔癌细胞产生谷胱甘肽，并导致对放射治疗的抵抗。临床病理检测p62/SQSTM1积聚可预测预后不良，有可能成为口腔鳞癌新的生物标志物。

Staining of p62/SQSTM1 and RB1CC1 was scored by using a tissue microarray of lung cancers. RB1CC1 is expressed only in the cytoplasm of lung cancers, suggesting poor prognosis of lung cancers. p62/SQSTM1 accumulation was further associated with the worse survival, especially the worst in the cases with both expressions of p62/SQSTM1 and RB1CC1. p62/SQSTM1 could become a biomarker of worse prognosis in lung cancer cases.In oral squamous cell carcinomas, p62/SQSTM1 contributed to induce glutathione in oral carcinoma cells, and to cause a resistance to radiation therapy. Clinico-pathological detection of p62/SQSTM1 accumulation could predict poor prognosis, and could be a new biomarker in the cases of oral squamous cell carcinoma.